

# Update on Asthma Management With a Focus on Inhaled Corticosteroids

## References

1. Michael J. Morris. Asthma. In: ; 2020. <https://emedicine.medscape.com/article/296301-overview#a1>
2. Tan DJ, Bui DS, Dai X, et al. Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis. *Eur Respir Rev*. 2021;30(159):200185. doi:10.1183/16000617.0185-2020
3. Crompton G. A brief history of inhaled asthma therapy over the last fifty years. *Prim Care Respir J*. 2006;15(6):326-331. doi:10.1016/j.pcrj.2006.09.002
4. *2021 GINA Report, Global Strategy for Asthma Management and Prevention.*; 2021:217.
5. *2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.*; 2020:322.
6. Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF, Pace W, Schatz M. Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program. *JAMA*. 2020;324(22):2301. doi:10.1001/jama.2020.21974
7. Lazarus SC. On-Demand versus Maintenance Inhaled Treatment in Mild Asthma. *N Engl J Med*. 2018;378(20):1940-1942. doi:10.1056/NEJMe1802680
8. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. *Lancet Lond Engl*. 2003;361(9363):1071-1076. doi:10.1016/S0140-6736(03)12891-7
9. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. *N Engl J Med*. 2000;343(5):332-336. doi:10.1056/NEJM200008033430504
10. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. *JAMA*. 1997;277(11):887-891.
11. Cusack RP, Satia I, O'Byrne PM. Asthma maintenance and reliever therapy. *Ann Allergy Asthma Immunol*. 2020;125(2):150-155. doi:10.1016/j.anai.2020.04.009
12. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. *N Engl J Med*. 2018;378(20):1865-1876. doi:10.1056/NEJMoa1715274
13. Bateman ED, Reddel HK, O'Byrne PM, et al. As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. *N Engl J Med*. 2018;378(20):1877-1887. doi:10.1056/NEJMoa1715275
14. Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. *N Engl J Med*. 2019;380(21):2020-2030. doi:10.1056/NEJMoa1901963
15. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. *The Lancet*. 2019;394(10202):919-928. doi:10.1016/S0140-6736(19)31948-8
16. Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. *Respir Res*. 2019;20(1):183. doi:10.1186/s12931-019-1159-y
17. Fingleton J, Hardy J, Baggott C, et al. Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. *BMJ Open Respir Res*. 2017;4(1):e000217. doi:10.1136/bmjresp-2017-000217
18. Lovinsky-Desir S, O'Connor GT. Evolving Strategies for Long-term Asthma Management. *JAMA*. 2020;324(22):2265. doi:10.1001/jama.2020.16895
19. Lin J, Zhou X, Wang C, Liu C, Cai S, Huang M. Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines. *Expert Rev Respir Med*. 2018;12(3):191-202. doi:10.1080/17476348.2018.1429921
20. Kesten S, Chapman KR, Broder I, et al. A Three-Month Comparison of Twice Daily Inhaled Formoterol Versus Four Times Daily Inhaled Albuterol in the Management of Stable Asthma. *Am Rev*

- Respir Dis.* 1991;144(3\_pt\_1):622-625. doi:10.1164/ajrccm/144.3\_Pt\_1.622
21. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *N Engl J Med.* 1997;337(20):1405-1411. doi:10.1056/NEJM199711133372001
  22. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am J Respir Crit Care Med.* 1996;153(5):1481-1488. doi:10.1164/ajrccm.153.5.8630590
  23. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. *The Lancet.* 1994;344(8917):219-224. doi:10.1016/S0140-6736(94)92996-3
  24. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. *N Engl J Med.* 2010;363(18):1715-1726. doi:10.1056/NEJMoa1008770
  25. Chipps B, Taylor B, Bayer V, et al. Relative efficacy and safety of inhaled corticosteroids in patients with asthma. *Ann Allergy Asthma Immunol.* 2020;125(2):163-170.e3. doi:10.1016/j.anai.2020.04.006
  26. Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med.* 2012;367(13):1198-1207. doi:10.1056/NEJMoa1208606
  27. Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. *N Engl J Med.* 2016;374(19):1822-1830. doi:10.1056/NEJMoa1511049
  28. Peters SP, Bleecker ER, Canonica GW, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. *N Engl J Med.* 2016;375(9):850-860. doi:10.1056/NEJMoa1511190
  29. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. *Thorax.* 2010;65(1):39-43. doi:10.1136/thx.2009.116608
  30. Price D, Musgrave SD, Shepstone L, et al. Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy. *N Engl J Med.* 2011;364(18):1695-1707. doi:10.1056/NEJMoa1010846
  31. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. *Am J Respir Crit Care Med.* 2019;199(4):433-445. doi:10.1164/rccm.201810-1944CI

## Update on Direct Oral Anticoagulants in Obesity

### References

1. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. *J Thromb Haemost.* 2016;14(6):1308-1313. doi:10.1111/jth.13323
2. Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. *J Thromb Haemost.* 2021;19(8):1874-1882. doi:10.1111/jth.15358
3. Di Nisio M, Vedovati MC, Riera-Mestre A, et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. *Thromb Haemost.* 2016;116(4):739-746. doi:10.1160/TH16-02-0087
4. Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. *J Thromb Thrombolysis.* 2021;51(2):349-358. doi:10.1007/s11239-020-02199-0
5. Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. *Ann Pharmacother.* 2020;54(4):344-350. doi:10.1177/1060028019886092
6. Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. *Lancet Haematol.* 2019;6(7):e359-e365. doi:10.1016/S2352-3026(19)30086-9
7. Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. *Thromb Res.* 2019;182:159-166. doi:10.1016/j.thromres.2019.08.021

8. Cohen A, Sah J, Lee T, et al. Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity. *J Clin Med*. 2021;10(2):200. doi:10.3390/jcm10020200

## Vancomycin Therapeutic Drug Monitoring

### References

1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2009;66(1):82-98. doi:10.2146/ajhp080434
2. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2020;77(11):835-864. doi:10.1093/ajhp/zxaa036
3. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. *Adv Drug Deliv Rev*. 2014;77:50-57. doi:10.1016/j.addr.2014.05.016
4. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2011;52(8):969-974. doi:10.1093/cid/cir078
5. Finch NA, Zasowski EJ, Murray KP, et al. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. *Antimicrob Agents Chemother*. 2017;61(12):e01293-17. doi:10.1128/AAC.01293-17
6. Neely MN, Kato L, Youn G, et al. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing. *Antimicrob Agents Chemother*. 2018;62(2):e02042-17. doi:10.1128/AAC.02042-17
7. Heil EL, Claeys KC, Mynatt RP, et al. Making the change to area under the curve-based vancomycin dosing. *Am J Health Syst Pharm*. 2018;75(24):1986-1995. doi:10.2146/ajhp180034
8. Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. *Clin Infect Dis*. 2006;42(Supplement\_1):S35-S39. doi:10.1086/491712